Total Payments
$19,926
2024 Payments
$21.44
Companies
56
Transactions
717
Medicare Patients
2,068
Medicare Billing
$339,103
Payment Breakdown by Category
Food & Beverage$11,317 (56.8%)
Research$7,292 (36.6%)
Consulting$895.84 (4.5%)
Travel$198.50 (1.0%)
Other$182.20 (0.9%)
Education$41.22 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $11,317 | 691 | 56.8% |
| Unspecified | $7,292 | 7 | 36.6% |
| Consulting Fee | $895.84 | 1 | 4.5% |
| Travel and Lodging | $198.50 | 1 | 1.0% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $182.20 | 14 | 0.9% |
| Education | $41.22 | 3 | 0.2% |
Payments by Type
General
$12,635
710 transactions
Research
$7,292
7 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $4,973 | 2 | $0 (2018) |
| GENZYME CORPORATION | $2,600 | 22 | $0 (2019) |
| Allergan, Inc. | $1,984 | 47 | $0 (2020) |
| Biogen, Inc. | $1,234 | 101 | $0 (2022) |
| Teva Pharmaceuticals USA, Inc. | $976.06 | 73 | $0 (2019) |
| UCB, Inc. | $750.14 | 49 | $0 (2019) |
| Novartis Pharmaceuticals Corporation | $698.22 | 44 | $0 (2019) |
| Genentech USA, Inc. | $588.89 | 24 | $0 (2021) |
| Amgen Inc. | $502.89 | 14 | $0 (2023) |
| EISAI INC. | $420.00 | 25 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $21.44 | 1 | ABBVIE INC. ($21.44) |
| 2023 | $187.79 | 3 | Amgen Inc. ($143.24) |
| 2022 | $99.03 | 1 | Biogen, Inc. ($99.03) |
| 2021 | $298.49 | 4 | Genentech USA, Inc. ($116.12) |
| 2020 | $18.23 | 1 | Allergan, Inc. ($18.23) |
| 2019 | $3,528 | 204 | Biogen, Inc. ($389.87) |
| 2018 | $8,076 | 238 | Eli Lilly and Company ($4,676) |
| 2017 | $7,698 | 265 | GENZYME CORPORATION ($2,415) |
All Payment Transactions
717 individual payment records from CMS Open Payments — Page 1 of 29
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 01/27/2024 | ABBVIE INC. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $21.44 | General |
| Category: BOTOX THERAPEUTIC | ||||||
| 11/17/2023 | Amgen Inc. | Aimovig (Biological) | Food and Beverage | In-kind items and services | $143.24 | General |
| Category: Neuroscience | ||||||
| 10/10/2023 | AbbVie Inc. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $28.64 | General |
| Category: NEUROSCIENCE | ||||||
| 09/22/2023 | AbbVie Inc. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $15.91 | General |
| Category: NEUROSCIENCE | ||||||
| 02/08/2022 | Biogen, Inc. | — | Food and Beverage | In-kind items and services | $99.03 | General |
| 11/20/2021 | Lundbeck LLC | VYEPTI (Biological) | Food and Beverage | In-kind items and services | $42.39 | General |
| Category: NEUROLOGY | ||||||
| 11/19/2021 | AbbVie Inc. | — | Food and Beverage | In-kind items and services | $33.93 | General |
| 10/07/2021 | Genentech USA, Inc. | — | Food and Beverage | In-kind items and services | $116.12 | General |
| 08/19/2021 | SK Life Science, Inc. | XCOPRI (Drug) | Food and Beverage | In-kind items and services | $106.05 | General |
| Category: Neurology | ||||||
| 01/13/2020 | Allergan, Inc. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $18.23 | General |
| Category: NEUROSCIENCE | ||||||
| 12/04/2019 | CSL Behring | Hizentra (Biological) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: Immunology | ||||||
| 11/14/2019 | Allergan Inc. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $3.48 | General |
| Category: HYPERHYDROSIS | ||||||
| 11/07/2019 | Allergan Inc. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $3.58 | General |
| Category: HYPERHYDROSIS | ||||||
| 10/31/2019 | Amgen Inc. | Aimovig (Biological) | Food and Beverage | In-kind items and services | $17.93 | General |
| Category: Neuroscience | ||||||
| 10/31/2019 | Supernus Pharmaceuticals, Inc. | TROKENDI XR (Drug) | Food and Beverage | Cash or cash equivalent | $8.29 | General |
| Category: AED | ||||||
| 10/24/2019 | Amgen Inc. | Aimovig (Biological) | Food and Beverage | In-kind items and services | $15.41 | General |
| Category: Neuroscience | ||||||
| 10/23/2019 | GE HEALTHCARE | — | Food and Beverage | Cash or cash equivalent | $19.45 | General |
| 10/21/2019 | Akcea Therapeutics, Inc. | TEGSEDI (Drug) | Food and Beverage | In-kind items and services | $20.23 | General |
| Category: NEUROLOGY | ||||||
| 10/18/2019 | Teva Pharmaceuticals USA, Inc. | AJOVY (Drug) | Food and Beverage | In-kind items and services | $16.39 | General |
| Category: Central Nervous System | ||||||
| 10/18/2019 | Bausch Health US, LLC | MIGRANAL (Drug) | Food and Beverage | In-kind items and services | $14.14 | General |
| Category: NEUROLOGY | ||||||
| 10/17/2019 | Sunovion Pharmaceuticals Inc. | APTIOM (Drug) | Food and Beverage | In-kind items and services | $15.79 | General |
| Category: CNS | ||||||
| 10/17/2019 | Amneal Pharmaceuticals LLC | RYTARY (Drug) | Food and Beverage | In-kind items and services | $14.84 | General |
| Category: NEUROLOGY | ||||||
| 10/10/2019 | UCB, Inc. | Briviact (Drug) | Food and Beverage | In-kind items and services | $20.56 | General |
| Category: Neurology | ||||||
| 10/10/2019 | Teva Pharmaceuticals USA, Inc. | AJOVY (Drug) | Food and Beverage | In-kind items and services | $13.93 | General |
| Category: Central Nervous System | ||||||
| 10/10/2019 | UCB, Inc. | Briviact (Drug) | Food and Beverage | In-kind items and services | $6.29 | General |
| Category: Neurology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF LY2951742 IN PATIENTS WITH CHRONIC MIGRAINE - THE REGAIN STUDY | Eli Lilly and Company | $4,973 | 2 |
| Case report from clinical practice - no protocol number | GENZYME CORPORATION | $732.96 | 1 |
| Case Study | GENZYME CORPORATION | $517.40 | 1 |
| A MULTICENTER, RANDOMIZED, OPEN LABEL EXTENSION STUDY TO EVALUATE THE LONG TERM SAFETY AND TOLOERABILITY OF ORAL UBROGEPANT IN THE ACUTE TREATMENT OF MIGRANE WITH R WITHOUT AURA | Allergan Inc. | $356.00 | 1 |
| A PHASE 23, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL AGN-241689 IN EPISODIC MIGRAINE PREVENTION. | Allergan Inc. | $356.00 | 1 |
| A PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED SINGLE ATTACK STUDY TO EVALUATE THE EFFICACY, SAFETY AND TOLERABILITY OF ORAL UBROGEPANT IN THE ACUTE TREATMENT OF MIGRAINE | Allergan Inc. | $356.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 10 | 554 | 6,933 | $315,855 | $88,152 |
| 2022 | 8 | 500 | 5,873 | $294,126 | $80,422 |
| 2021 | 9 | 519 | 7,439 | $336,150 | $95,751 |
| 2020 | 9 | 495 | 5,875 | $284,870 | $74,776 |
Total Patients
2,068
Total Services
26,120
Medicare Billing
$339,103
Procedure Codes
36
All Medicare Procedures & Services
36 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0585 | Injection, onabotulinumtoxina, 1 unit | Office | 2023 | 12 | 6,300 | $88,200 | $31,321 | 35.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 209 | 268 | $100,500 | $27,011 | 26.9% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 94 | 94 | $37,130 | $8,594 | 23.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 105 | 116 | $29,580 | $8,026 | 27.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 33 | 33 | $16,335 | $4,345 | 26.6% |
| 95886 | Needle measurement of electrical activity in arm or leg muscles, complete study | Office | 2023 | 27 | 34 | $12,920 | $2,906 | 22.5% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 26 | 26 | $12,220 | $2,861 | 23.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 25 | 25 | $14,375 | $2,176 | 15.1% |
| 95885 | Needle measurement of electrical activity in arm or leg muscles, limited study | Office | 2023 | 11 | 15 | $3,825 | $820.91 | 21.5% |
| 96127 | Assessment of emotional or behavioral problems | Office | 2023 | 12 | 22 | $770.00 | $92.08 | 12.0% |
| J0585 | Injection, onabotulinumtoxina, 1 unit | Office | 2022 | 13 | 5,299 | $74,186 | $25,796 | 34.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 200 | 258 | $96,750 | $25,631 | 26.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 112 | 112 | $64,400 | $13,837 | 21.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 86 | 102 | $26,010 | $7,062 | 27.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 29 | 29 | $14,355 | $4,296 | 29.9% |
| 95886 | Needle measurement of electrical activity in arm or leg muscles, complete study | Office | 2022 | 20 | 22 | $8,360 | $1,913 | 22.9% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 23 | 23 | $9,085 | $1,773 | 19.5% |
| 96127 | Assessment of emotional or behavioral problems | Office | 2022 | 17 | 28 | $980.00 | $114.93 | 11.7% |
| J0585 | Injection, onabotulinumtoxina, 1 unit | Office | 2021 | 14 | 6,800 | $95,200 | $33,035 | 34.7% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 194 | 280 | $105,000 | $28,727 | 27.4% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 96 | 96 | $55,200 | $12,993 | 23.5% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 105 | 136 | $34,680 | $9,543 | 27.5% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 29 | 31 | $15,345 | $4,225 | 27.5% |
| 99203 | New patient outpatient visit, total time 30-44 minutes | Office | 2021 | 31 | 31 | $12,245 | $3,004 | 24.5% |
| 95886 | Needle measurement and recording of electrical activity of muscles of arm or leg complete study | Office | 2021 | 24 | 27 | $10,260 | $2,490 | 24.3% |
About Dr. Dario Zagar, M.D
Dr. Dario Zagar, M.D is a Neurology healthcare provider based in Fairfield, Connecticut. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/03/2006. The National Provider Identifier (NPI) number assigned to this provider is 1093773756.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Dario Zagar, M.D has received a total of $19,926 in payments from pharmaceutical and medical device companies, with $21.44 received in 2024. These payments were reported across 717 transactions from 56 companies. The most common payment nature is "Food and Beverage" ($11,317).
As a Medicare-enrolled provider, Zagar has provided services to 2,068 Medicare beneficiaries, totaling 26,120 services with total Medicare billing of $339,103. Data is available for 4 years (2020–2023), covering 36 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurology
- Location Fairfield, CT
- Active Since 05/03/2006
- Last Updated 08/01/2008
- Taxonomy Code 2084N0400X
- Entity Type Individual
- NPI Number 1093773756
Products in Payments
- LEMTRADA (Drug) $2,307
- TECFIDERA (Drug) $722.95
- OCREVUS (Biological) $472.77
- Briviact (Drug) $449.65
- Fycompa (Drug) $420.00
- AJOVY (Drug) $379.05
- ACTHAR (Biological) $369.44
- Aimovig (Biological) $355.86
- TROKENDI XR (Drug) $344.52
- TYSABRI (Biological) $327.29
- BOTOX CHRONIC MIGRAINE (Drug) $307.52
- AIMOVIG (Biological) $295.78
- Rebif (Biological) $292.79
- Hizentra (Biological) $256.57
- APTIOM (Drug) $252.83
- GILENYA (Drug) $244.27
- Zinbryta (Biological) $234.37
- BOTOX THERAPEUTIC (Biological) $225.39
- TEV-48125 (Biological) $220.69
- SOLIRIS (Drug) $214.06
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurology Doctors in Fairfield
Peter Mcallister, M.d, M.D
Neurology — Payments: $2.3M
Neurology $2.3M
P. Christopher Gottschalk, M.d, M.D
Neurology — Payments: $400,249
Neurology $400,249
Jeffrey Gross, M.d, M.D
Neurology — Payments: $191,862
Neurology $191,862
Dr. Nicholas Blondin, M.d, M.D
Neurology — Payments: $144,704
Neurology $144,704
Srinath Kadimi, M.d, M.D
Neurology — Payments: $44,527
Neurology $44,527
Mrs. Ruby Ali, M.d, M.D
Neurology — Payments: $18,050
Neurology $18,050